lifestyle.realie.org

Author: SOLIGENIX, INC.

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

April 2, 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

March 31, 2026
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet’s Disease

March 26, 2026
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

March 23, 2026
Soligenix Announces HyBryte™ Clinical Summary Published in “Expert Opinion on Investigational Drugs”

March 19, 2026
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

March 10, 2026
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet’s Disease

February 26, 2026
Soligenix to Present at BIO Investment & Growth Summit

February 24, 2026
Soligenix Details Recent Progress and Upcoming Milestones

February 12, 2026
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet’s Disease Published in Rheumatology (Oxford)

December 20, 2025